Nerium International LLC is rolling out its fifth product, an Age-Defying Eye Serum that contains a patent-pending molecule developed for the anti-aging company.
The hero ingredient is SIG-1191, a molecule that acts as an antioxidant while also hydrating the skin. In third-party clinical trials, Age-Defying Eye Serum was found to combat signs of aging that commonly appear around the eyes, such as crow’s feet, puffiness and dark circles.
“We have the global exclusive rights for every one of our patents,” Jeff Olson, Founder and CEO, said in a statement. “Because we license the patents and the sourcing, no one else can replicate our products.”
The credit for developing SIG-1191 goes to Dr. Jeffry Stock, a Princeton University biochemist, and the team at Signum Biosciences, who previously discovered SIG-1273, a key ingredient in Nerium’s Optimera Formula anti-aging and contouring creams.
Signum is also behind the patented coffee seed extract in EHT Age-Defying Supplement, which protects against mental decline and boosts overall brain health. Following an initial rollout in the U.S., Nerium will launch the proprietary formula in Canada next month.